Compare ADMA Biologics Inc (ADMA) vs Suncor Energy Inc. (SU) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ADMA Biologics Inc vs Suncor Energy Inc. — how do they compare? ADMA Biologics Inc trades at $9.26 (market cap $2.13B), while Suncor Energy Inc. trades at $58.5 (market cap $66.94B). The key difference: Suncor Energy Inc. is far larger — about 31.4× ADMA Biologics Inc's market cap, and Suncor Energy Inc. pays a 2.98% dividend while ADMA Biologics Inc pays none. Which is the better fit depends on your goals.
| ADMA | SU | |
|---|---|---|
Market Cap | $2.13B | $66.94B |
Sector | Health | Energy |
52-Week High | $20.38 | $69.73 |
52-Week Low | $7.60 | $38.17 |
Enterprise Value | $2.20B | $75.07B |
Dividend Yield | — | 2.98% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADMA trades at $9.16, up 2.35% today, with a bullish technical signal from moving averages and oscillators. The company reported strong profitability with a 32.43% net income margin and 43.3% ROE for 2025, though recent EPS results were mixed. Analyst consensus is strongly bullish with an $19.00 price target, but multiple class action lawsuits filed in July 2026 alleging securities fraud create significant near-term uncertainty.
The stock offers substantial upside to analyst targets if legal challenges are resolved favorably, supported by robust fundamentals and projected cash flow growth. Primary risks include the outcome of ongoing litigation and potential reputational damage. Investors should weigh strong financial performance against elevated legal and sentiment risks before establishing a position.
Suncor Energy (SU) trades at $56.66, up 2.92% today, with a bullish technical signal despite mixed moving averages. The stock shows solid fundamentals with a P/E of 14.82, net margin of 11.62%, and consistent dividend payments, including a recent $0.60 distribution. Recent earnings beat expectations in Q3 and Q4 2025, though Q1 2026 missed estimates. Analyst consensus is strongly positive with 74% buy ratings.
Outlook remains favorable due to attractive valuation and strong cash flow, but risks include oil price volatility and operational incidents like the recent Sarnia refinery fire. Earnings growth and disciplined capital allocation are key catalysts for upside, while macroeconomic pressures pose headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ADMA Biologics Inc
ADMA Biologics is a biopharmaceutical company specializing in plasma-derived therapies for immunodeficient patients. Key products like ASCENIV and BIVIGAM treat primary humoral immunodeficiency and help prevent infectious diseases.
Read more on ADMA →About Suncor Energy Inc.
Suncor Energy Inc is an integrated energy company. The company's operations include oil sands development, production and upgrading, offshore oil and gas, petroleum refining in Canada and the U.S. and the company's PetroCanada retail and wholesale distribution networks. The company is developing petroleum resources while advancing the transition to a low-emissions future through investment in power, renewable fuels and hydrogen. It also conducts energy trading activities focused principally on the marketing and trading of crude oil, natural gas, byproducts, refined products and power.
Read more on SU →
